A Review on Carcinogenic Impurities Found in Marketed Drugs and Strategies for its Determination by Analytical Methods

[1]  A. Pawar,et al.  A brief review on: Separation techniques chromatography , 2020 .

[2]  R. Tennant,et al.  Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data. , 2020, Regulatory toxicology and pharmacology : RTP.

[3]  A. Deep,et al.  An overview: LC-ms as tool of sample extraction and quantification in bioanalytical laboratories , 2020 .

[4]  Andrea V Eads.  Pharmacists are key in interpreting clinical implications of N-nitrosodimethylamine contamination in medications. , 2020, Journal of the American Pharmacists Association : JAPhA.

[5]  Pramod Kumar,et al.  Regulatory Updates and Analytical Methodologies for Nitrosamine Impurities Detection in Sartans, Ranitidine, Nizatidine, and Metformin along with Sample Preparation Techniques , 2020, Critical reviews in analytical chemistry.

[6]  Ho‐Sang Shin,et al.  Determination of N-nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography-tandem mass spectrometry. , 2020, Journal of pharmaceutical and biomedical analysis.

[7]  J. Colombo,et al.  Medicine and Media: The Ranitidine Debate , 2020, Clinical and translational science.

[8]  Ahmet Çelik.  ACEi/ARB naif hastalarda sakubitril/valsartan başlanabilir mi? , 2020 .

[9]  Naseem A. Charoo,et al.  Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities , 2019, AAPS PharmSciTech.

[10]  M. Parr,et al.  NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N‐nitrosamines , 2019, Journal of pharmaceutical and biomedical analysis.

[11]  G. Tchernev,et al.  Drug-Induced Melanoma: Irbesartan Induced Cutaneous Melanoma! First Description in the World Literature! , 2019, Open access Macedonian journal of medical sciences.

[12]  D. Venkata Ramana,et al.  Validation of Analytical Procedures- A Review , 2018 .

[13]  Andrew Teasdale,et al.  ICH M7: Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk , 2017 .

[14]  H. Khan.  Analytical Method Development in Pharmaceutical Research: Steps involved in HPLC Method Development , 2017 .

[15]  J. Ali,et al.  UHPLC: Applications in Pharmaceutical Analysis , 2017 .

[16]  J. Ali,et al.  Identification of Impurities and Degradation Products in Pharmaceutical Products- Role of Hyphenated Techniques , 2017 .

[17]  W. Mitch,et al.  Oral intake of ranitidine increases urinary excretion of N-nitrosodimethylamine. , 2016, Carcinogenesis.

[18]  R. Saudagar,et al.  Review on Guideline on Elemental Impurities , 2016 .

[19]  .. S.R.Chaudhari,et al.  Impurities in Pharmaceuticals- A Review. , 2013 .

[20]  J. Akhtar,et al.  Impurity Profiling With Use of Hyphenated Techniques , 2012 .

[21]  M. Stiborová,et al.  The binding affinity of carcinogenic N-nitrosodimethylamine and N-nitrosomethylaniline to cytochromes P450 2B4, 2E1 and 3A6 does not dictate the rate of their enzymatic N-demethylation. , 2010, General physiology and biophysics.

[22]  Lutz Müller,et al.  Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity. , 2009, Toxicology letters.

[23]  D. Elder,et al.  Drug substances presented as sulfonic acid salts: overview of utility, safety and regulation , 2009 .

[24]  H. Bartsch,et al.  Relevance of N-nitroso compounds to human cancer: exposures and mechanisms. Proceedings of the IXth International Symposium on N-Nitroso Compounds. Baden, Austria, 1-5 September 1986. , 1987, IARC scientific publications.